|
|
MicuRx Pharma Picks Next-Gen MRSA Antibiotic Candidate
publication date: Aug 19, 2008
MicuRx Pharmaceuticals, Inc., a privately held company based in the US and Shanghai, China, named its first preclinical development candidate. MicuRX is developing next-generation antibiotics aimed at multi-drug resistant gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). At the same time, the company moved into a new 10,000 square foot laboratory in ZhangJiang HighTech Park in Shanghai. The company had previously presented at the ChinaBio® Investor Forum held in Shanghai last December. More details...
Stock Symbol: (NYSE: PFE)
|
ChinaBio® Events
April 14, 2010 Guangzhou, China Suzhou, China June 23-24, 2010
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners
![]()
|